Volume 4, Issue 6, 2026

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

HEPATITIS- ITS CAUSES, TYPES AND EFFECTS ON HUMAN HEALTH IN BALOCHISTAN, PAKISTAN-A-REVIEW

Sadia Mengal[*1], Samar Ali[2], Nimra Fazal[3], Habiba Taj[4], Aurangzeb Ashraf[5]

*[*1,2,3,4,5]Faculty of Physical and Environmental Sciences, Department of Chemistry, University of Balochistan, Quetta Pakistan*

DOI: https://doi.org/10.5281/zenodo.20823662

Keywords

Viral hepatitis, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, Causes, and effects on Human health, Balochistan, Pakistan.

Article History

Received: 25 April 2026
Accepted: 04 June 2026
Published: 21 June 2026

Corresponding Author: *
Sadia Mengal

Abstract

Hepatitis is a major public health concern in worldwide and remains one of the leading major causes of liver-related morbidity and mortality, particularly in developing countries such as Pakistan. This review summarizes the causes, types, transmission routes, clinical manifestations treatment, and effects of viral hepatitis on human health, with a special focus on Balochistan, Pakistan, where the disease burden is considerably high. Viral hepatitis is primarily caused by five hepatotropic viruses: hepatitis A (HAV), hepatitis B (HBV), hepatitis C (HCV), hepatitis D (HDV), and hepatitis E (HEV), each differing in transmission, disease. Major contributing factors, are the high prevalence of hepatitis in Balochistan include inadequate healthcare facilities, poor sanitation, unsafe drinking water, contaminated blood transfusions, unsterilized medical and dental equipment, unsafe injection practices, intravenous drug use, and low vaccination coverage. While acute hepatitis A and E are mostly self-limiting, chronic infections of HBV and HCV have the potential to develop into liver fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure, and can have a major impact on quality of life and healthcare costs. The review also discusses public awareness, safe healthcare practices, early diagnosis, and antiviral therapies, as well as the challenges associated with disease control in the province. Improvements in surveillance systems, vaccination coverage, sanitation, safe medical practices, and screening and treatment access are all critical for reducing the burden of hepatitis and meeting the goal of the World Health Organization.

Introduction

Viral hepatitis is the inflammation of the liver that occurs due to viruses. At present there are five hepatotropic viruses (hepatitis A, B, C, D, and E) have been recognized, each transmitted through distinct pathways. While some forms of acute hepatitis may resolve spontaneously, others can progress to chronic infection (Cheung et al., 2020). Significant scientific advancements over recent decades have facilitated the development of preventive strategies, vaccination protocols, passive immunization techniques, and latterly, promising therapeutic interventions for certain hepatitis variants. The fundamental understanding of viral mechanisms and virus-cell interactions has enabled medical science to address what was previously considered an insurmountable human affliction. The progress in hepatitis prevention and treatment potentially represents an exemplary model of successful translational research (Pisano et al., 2021). Nevertheless, viral hepatitis remains a significant global health challenge, affecting millions and causing numerous fatalities from acute and chronic infections, cirrhosis, and hepatocellular carcinoma (Flichman et al., 2021).

The disease leads to the damage and dysfunction of liver cells hence proper nutrition is important. The work of liver in metabolic processes, clean- up and protein production is extremely important, carbohydrate and fat. They may be disrupted during the episode of AVH

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

and, hence, adhering to a special diet will enable an individual to avoid excessive burdening of the liver (Razzokberganova et al.,2025).

The world Is infected with too many people having hepatitis infection of about 400 million. Whenever these infections are not treated, whether by choice or otherwise, it has been found out that in most extreme infections, they tend to cause deaths.The high mortality rate among the hepatic infections is because of long term effects which might cause liver cirrhosis or HCC (Hepatocellular Carcinoma). It is estimated that there is a persistent infection with HBV of 257 and 291 million people, therefore, Individuals are at an increased risk of progressing to cirrhosis and hepatocellular carcinoma (HCC). Globally, one-third of HCC-related fatalities are attributed to hepatitis B virus (HBV).Almost all the developing nations like Pakistan have a high hepatitis infection rate, despite the fact that, most of the developed and rich nations have been able to effectively bring down the rate of this viral infection that leads to liver disease. There have been reported and diagnosed high cases of hepatitis patients and still many have not been diagnosed or have not been to any hospitals in the country due to lack of or no medical facility or awareness (Ali et al., 2024).

Causes of Viral hepatitis



The viral infection Hepatitis A is a type of picornavirus primarily responsible for causing hepatitis and is found in most regions of the world. Most frequently, the disease is spread via oral consumption or person-to-person contact following fecal contamination of the skin or mucous membranes, food or water contamination is infrequent. Hepatitis A is prevalent in developing nations, where most people contract it as children. On the other hand, the adult population of the developed countries show a declining exposure rate with improved hygiene and sanitation. Exporting food that is notable from nations with an increased epidemic status as part of infections to other nations having lower rates of infection is another potential significant cause of infection. The virus settles in the liver and is discharged into the bile after being repeatedly ingested in the gastrointestinal tract. The virus's cellular immune response results in the death of infected hepatocytes, which causes symptoms and indicators of the illness to manifest (Cuthbert et al.,2001).

There are some special management issues in regard to the infection of hepatitis B during pregnancy. The areas of care like effects of hepatitis B on mother and fetus, the impact of pregnancy on the hepatitis B infection process and its complications, as well as the prevention of prenatal infection and the treatment of hepatitis B in pregnant women to be considered. There are currently too few studies on these topics; the majority are of Far Eastern origin, and many are very limited, although few have provided useful information. Although the acute hepatitis B virus (HBV) infection in pregnant women does not seem to differ much from that of the general population of adults, the later the acute infection develops during pregnancy, the more HBV is passed on to the fetus. Pregnant women often do not have a severe CHBV infection, but it may worsen shortly after birth. Women who have high

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

viraemia are more likely to experience prenatal transmission this could be one of the causes of the low but consistent failure rate of contemporary immunoprophylaxis techniques.(Jonas et al.,2009). The mechanism by which hepatitis C virus (HCV) contributes to atherosclerosis and cardiovascular events remains unclear. This research aimed to determine HCV's direct impact on cardiovascular risk and its relationship with pro and anti-inflammatory cytokines in infected individuals. The study population consisted of non-obese (BMI<30), non-diabetic patients monoinfected with HCV genotype 1 who had not received previous treatment, alongside control subjects from blood donor populations. Researchers excluded participants with pre-existing cardiovascular diseases, hypertension, chronic renal failure, cancer, and those taking lipid-lowering medications or immunosuppressant. Participants were matched according to age, BMI, systolic and diastolic blood pressure, fasting glucose, and lipid profiles (Lima et al., 2013).

Hepatitis E is a virus that causes infection of liver; the infection is caused by an agent that is known as hepatitis E virus (HEV) which is a small non enveloped virus that has single stranded RNA. There are four genotypes but a single serotype in the virus. The genotype 1 and 2 only infect human beings because genotype 3 and 4 infect pigs and some other mammal also got infected. Numerous aspects of HEV pathogenicity and biology were identified through the use of animal models, cell transfected with HEV DNA, and analogy with other related viruses, despite its ineffective growth in cell culture.HEV appears not to be cytopathic and liver injury in the course of hepatitis E may be due to host-immune mediated injury. HEV infection is have an endemic character in the areas of poor sanitation, and it appears both as an outbreak, Additionally, as isolated instances of extreme self-sufficient hepatitis. Most often, impure drinking water is the means of oral transmission of feces. Usually affecting young adults, and most severe in pregnant women (Aggarwal et al.,2011).

Effects of hepatitis in different areas in Balochistan



Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Effects of hepatitis A and B for different areas of district Balochistan, Kech , Turbat

The problem of hepatitis infection among the worldly population has been critically growing due to several human negligent approaches toward the viral infections of liver. But the developed nations have managed to control the prevalence of liver infections through their prudent prevention strategies; almost all the nations who are still underdeveloped like Pakistan are still endemic to the viral infection of the liver (hepatitis). Hepatitis affects millions of individuals globally each year. Among those infected, approximately half go on to experience hepatocellular carcinoma and cirrhosis. The number of hepatitis infections is increasing daily in Pakistan, especially in the Kech district (Turbat), where reports indicate that hundreds of individuals are infected with hepatitis. A larger portion of the population remains unaware that they are infected, and as a result, they continue transmitting the infection to their families, relatives, and others they encounter. A significant factor contributing to the increasing cases of hepatitis infections in the population of Kech (Turbat) and other heavily affected districts of Pakistan is the lack of understanding regarding the risk factors and transmission methods of hepatitis viruses. The improper handling of hairstyling tools, the re-use of non-sterilized dental and surgical equipment, the transfusion of unscreened blood, the reuse of single-use syringes, and the consumption of unsafe water and food are significant contributors to the transmission of viral hepatitis infections. Government-supported initiatives aimed at raising awareness among the population regarding these risk factors can greatly assist the nation in eliminating hepatic infections (Hasni et al.,2024).

Effects of hepatitis B and C for District Quetta Balochistan

Hepatitis B virus and Hepatitis C virus are infections affecting the liver. These infections may initially present without symptoms, but can eventually lead to yellowing of skin, mucous membranes and eye conjunctiva, reduced appetite and exhaustion, manifesting as either short-term or chronic infection. This investigation analyzed the socioeconomic factors contributing to HBV and HCV prevalence in Quetta Balochistan. Researchers interviewed 300 patients from those registered at Bolan Medical College and Civil hospital, collecting primary information via questionnaires and statistical instruments. Findings indicated that primary transmission routes for hepatitis included using shared personal razors from infected individuals, common nail tools from others, dental procedures, receiving contaminated blood transfusions, unsafe surgical procedures, sharing toothbrushes in domestic settings, consuming unwashed produce, utilizing non-sterile injections, and injecting substances (Ahmed et al., 2017).

Effect of HAV, HBV, HCV in Different Ethnic Communities in the Panjgur District of Balochistan

Hepatitis represents a significant health concern, and this investigation aimed to examine the occurrence of HAV, HBV, and HCV among main cultural groups (Brahui, Baloch, Pashtun, Punjabi Sindhi) in District Panjgur, with particular focus on linked risk elements and sub-clinical manifestations. The research revealed that male prevalence was considerably higher at 32.77% (370/1129) in comparison to females at 27.63% (312/1129). Within the 1129 examined cases, 20.28% (229) were diagnosed with hepatitis A, 33.21% (375) presented HBV infection, and 6.90% (78) exhibited HCV infection. Participants were categorized into three chronological divisions: Group-I (1->20 years), Group-II (21->40 years), and Group-III (41->60 years). The greatest contamination frequencies were documented in Group-II (21-40 years). Additionally, the research noted that the majority of patients demonstrated substantial cleanliness deficits. Primary risk elements for viral hepatitis transmission included non-sterilized clinical and oral tools, injuries, hematological transfers, and dangerous intimate behaviors. The predominant sub-clinical characteristics observed were elevated temperature, skeletal discomfort, jaundice, dark urine, and abdominal discomfort. The research determined that the proportion of service individuals with disabilities was 1.61 (Nazeer et al., 2023).

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Effect of hepatitis in different areas in Pakistan

Acute hepatitis variants A and E remain clinically indistinguishable from other pathogens that cause acute viral hepatitis. WHO data indicates that HAV and HEV occur globally at rates of 1.4 million and 20 million cases annually, resulting in approximately 100,000 and 60,000 deaths per year, respectively. Mortality rates are particularly high among pregnant women. Unfortunately, community-based studies are limited, with most information on HAV and HEV distribution in Pakistan originating from hospital-based research. As a result, statistical information varies between reports. Nevertheless, HAV and HEV continue to be endemic in Pakistan. Hepatitis A constitutes 50-60% of acute viral hepatitis cases among young Pakistanis. Due to early life contact, approximately 96% of individuals demonstrate evidence of HAV exposure (HAV IgG positive) by age 5. In contrast, HAV causes acute hepatitis infection in 3.5-4% of older individuals, and roughly 98-100% of adults show evidence of HAV exposure during adulthood. Acute HAV infection commonly manifests without symptoms or resolves spontaneously. However, among 2,735 confirmed cases of acute HAV documented between 1991 and 1998 at a Tertiary Care Hospital in Pakistan, 232 children required hospitalization, with a 36.7% mortality rate. This finding emphasizes the need for improved sanitation, clean water access, and timely vaccination of children against hepatitis A virus in countries such as Pakistan (Butt et al., 2015). Hepatitis B and C account for over three-quarters of cirrhosis and hepatocellular carcinoma (HCC) in the WHO EMRO region. Various studies conducted in Pakistan have reported different prevalence estimates, likely due to differences in research methodologies, sample sizes, study contexts, and interactions with various risk factors. The prevalence of hepatitis C virus has been reported to range between 0.4-1.4% in most studies, with one exception reporting 4.0% of healthy children possessing reactive anti-HCV antibody out of 538 children in Myo Hospital, Lahore (Subhan et al., 2015).

Effects of hepatitis B in KP Pakistan

Hepatitis B is considered the most dangerous of the five hepatitis variants because its clinical manifestations often go undetected. It possesses the capability to incrementally harm hepatic tissue over time without being discovered. Within the KP region of Pakistan, hepatitis B represents one of the primary elements leading to hepatic complications, exhibiting a mean prevalence figure of 2.70 percent (Khan et al., 2018).

Types of Viral hepatitis

- Hepatitis A (HAV)
- Hepatitis B (HBV)
- Hepatitis C (HCV)
- Hepatitis D (HDV)

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

- Hepatitis E (HEV)



Hepatitis A (HAV)

Hepatitis A Virus is a RNA virus that is non-enveloped and single-stranded. Hepatitis A virus is classified within the Picornaviridae family, genus Herpesvirus and is primarily transmitted through a fecal-oral route of transmission, individual-to-individual interaction or through ingestion of tainted nutrition or liquid. Serological evidence of prior infection is remarkably prevalent globally, although the distribution varies significantly across geographic regions and demographic groups. Typical acute HAV infection resolves on its own. Advanced age, nevertheless, has been identified as the principal risk element for manifesting symptomatic illness, though catastrophic hepatic insufficiency has also been documented. Management is primarily prophylactic through immunization prior to potential exposure and vaccination or HAV immunoglobulin to establish active and passive protection following an exposure (Odenwald et al., 2022).

Hepatitis B (HBV)

The Hepatitis B Virus (HBV) causes hepatitis B infection; the latter is a deoxyribonucleic acid (DNA) virus, and it follows the Orthohepadnavirus genus and Hepadnaviridae family (Paul et al., 2022). Transmission of the hepatitis B is by means of sex, contaminated blood or an infected mother to the child.HBV can trigger a short term or acute liver infection but it is also capable of triggering a chronic liver infection and result in chronic or long-lasting infection (Martin et al., 2020). The burden of HBV disease is decreasing in the developed world because to vaccination, but early exposures and mother-to-child (vertical) transmission of the virus keep disease incidence relatively high in endemic nations. The majority significant condition that pre-determines the outcome of the disease is the time of HBV infection because most of the perinatally infected people develop the chronic infection of hepatitis B in contrast to most of the adults who effortlessly clear the virus. The antiviral agents are able to avert the liver damage, multiplication of the viruses. Nevertheless, even now there is no cure that would allow to eradicate HBV infection, and diverse and numerous experimental medicines are being created that will, maybe, acquire certain therapeutic importance in the future. There is also a wide-ranging health plan to eradicate HBV, which is being initiated in every area of the world by

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

increasing the percentage of vaccination, diagnosis, and treatment (Paul et al., 2022).

Hepatitis C (HCV)

The Hepatitis C virus (HCV), a diminutive, monofilament, encased RNA virus, belonging to the flavivirus classification and exhibiting substantial genetic diversity, constitutes the etiological agent of hepatitis C infection. Seven distinct HCV genotypes have been identified. Genotype 1 represents the predominant variant in both the US and global contexts, with prevalence rates approximating 75 percent and 46 percent, respectively. The geographical variability in distribution patterns of different genotypes merits consideration, as therapeutic approaches are often customized according to specific genotypes. The HCV RNA genomic material demonstrates elevated mutation frequencies, potentially facilitating immune evasion mechanisms. Transmission can occur via blood contact through mucosal surfaces, albeit with reduced efficiency. Evidence indicates HCV presence in oral secretions, reproductive fluids, lactation products and additional physiological liquids, although these substances are not considered primary vehicles for pathogen transmission (Schillie et al., 2020).

Hepatitis D (HDV)

The causation of hepatitis D infection is linked to Hepatitis D virus (HDV), which is composed of a singular strand, encased RNA. HDV constitutes the most diminutive virus known to cause human infection, and is generally classified as a satellite virus owing to its absolute reliance on the HBV life cycle for reproduction (Odenwald et al., 2022). Similar to HBV, HDV spreads through the parenteral route via exposure to contaminated blood or body fluids and necessitates only a minimal viral burden to initiate infection (Alomar et al., 2021). The transmission process parallels that of HBV, and may occur as concurrent infection with HBV (i.e., coinfection) or may later impact individuals with established persistent HBV infections (i.e., superinfection). This temporal association with HBV infection affects the disease trajectory of HDV infection, with superinfection often resulting in a hastened clinical decline characterized by progressing liver inflammation, scarring, and the ultimate emergence of cirrhotic complications, including HCC. Present HDV management approaches emphasize prevention and HBV control, as HDV is wholly dependent on the HBV lifecycle; nevertheless, targeted HDV interventions are currently being researched (Paul et al., 2022).

Hepatitis E (HEV)

Hepatitis E virus (HEV) represents a small, nonenveloped virus containing a single-stranded RNA genome that is responsible for hepatitis E infection of the liver. The virus is classified into four genotypes within a single serotype. Genotypes 1 and 2 exclusively infect humans, whereas genotypes 3 and 4 have a broader host range, affecting both humans and swine, as well as various other mammalian species. Given HEV's limited capacity for cell culture propagation, researchers have elucidated certain features of its biological properties and disease mechanisms through alternative approaches, including animal model systems, cell transfection experiments, and comparative analyses with phylogenetically related viral agents. Hepatitis E virus has never seemed to be cyiopathic and liver damage in the case of hepatitis E could be host-immune mediated. HEV infection is quite prevalent in nations with inadequate sanitation, and it manifests as outbreaks and occasional cases of extreme self-contained hepatitis. The water for consumption is typically the means of feco-oral transfer. It is usually observed in young adults, and it is specifically dangerous during pregnant women and the individuals who have an underlying illness of liver cirrhosis. The condition is increasingly being diagnosed in the developed world. It also manifests itself sometimes as single cases, mainly among the older men who have other disorders. These also seem to be connected with the zoonotic transmission. Chronic infection is a phenomenon that has been familiar with immunosuppressed individuals in these areas and could develop into liver cirrhosis. Serologic diagnostics, such as IgM anti-HEV and immunoglobulin (Ig)G, consequently, might still be improved in terms of sensitivity and specificity when applied specifically in developed countries with regard to exposure and recent infection to HEV. There are two recombinant protein vaccines which have successfully undergone trials in humans, yet to be marketed. The recent past should be reviewed to allow the

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

study of this elusive agent to be improved since cell-culture systems of HEV have recently been developed (Aggarwal et al, 2011.)

BMC QUETTA BALOCHISTAN



Tests Performed by ELISA Method by BMC, Hospital during 2017 (Kalsoom et al.,2022).

Month	Test performed	Hepatitis B	Hepatitis C	Male	Female	percentage
January	376	51	18	230	146	18.35
March	410	89	28	256	154	28.53
May	532	104	40	301	231	27.07
July	338	60	38	205	133	28.99
September	379	59	37	209	170	25.32
November	490	77	37	311	131	15.79

Treatment of Hepatitis

Hepatitis A

The hepatitis A virus spreads through fecal-oral routes, and food can occasionally be a source of outbreaks. Symptoms are usually absent in children, but the chances of experiencing symptoms generally increases with age. While most individuals recover within two months post-infection, approximately 10 to 15 percent may experience a relapse during the first six months. The hepatitis A virus does not typically lead to chronic infections or chronic liver disease. The preferred treatment is supportive care. The prevention and Centers for Disease Control along with the American Academy of Pediatrics recommend that all children aged 12 to 23 months receive routine vaccinations, along with specific at-risk populations.. The Hepatitis A vaccine is usually necessary for most situations involving postexposure prophylaxis; in particular cases, immunoglobulin may be the more suitable choice(Matheny et al. 2012).

Hepatitis B

Hepatitis B viral disease also represents a significant worldwide health issue contributing

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

to the progression of the acute-to-chronic liver inflammation, severe hepatic system collapse, and mortality. Contaminated blood products and bodily secretions constitute the primary mechanisms through which maternal transmission occurs to offspring. Research indicates that evaluation for hepatitis B viral presence ought to be implemented among expectant mothers, youth, and mature individuals with elevated probability of persistent infection (Guvenir et al.,2020).

The hepatitis B viral disease remains a significant medical concern worldwide. Currently, two principal classifications of sanctioned medical interventions exist: interferons (IFNs) and nucleos(t)ide structural mimics (NAs). These medical protocols assist in suppressing HBV multiplication and averting complications including scarring of liver tissue, hepatic dysfunction, malignant liver cell growth (HCC), and death. Nevertheless, these interventions fail to completely eradicate the pathogen, maintaining a possibility for HCC development. The scholarly analysis examines contemporary insights regarding the harmlessness, therapeutic efficacy, and medical implementations of hepatitis B management. It further explores the constraints of existing therapies, deficiencies in current research, and future potential for eliminating hepatitis B (Suk-Fong et al.,2019).

Hepatitis C

One of the primary chronic liver conditions is attributed to the hepatitis C virus, and reported that more than 170 million individuals globally are infected with this virus. It is also a major reason for liver transplantation. The complications arising from a chronic hepatitis C infection encompass cirrhosis, hepatic decompensation, and hepatocellular carcinoma (Burstow et al.,2017).

It needs appropriate medication to prevent the advancement of the diseases and its complications. Old standard of cares only consisted of combination therapy involving interferon and ribavirin (RBV) based treatment that had minimal combinations of cure and involved irritating side effects. The era of direct-acting (DAA) began in 2011 when first-generation NS3/4A protease inhibitor was released. They highly reduced patient clinical results specifically for genotype 1 infection which represents the most common genotype worldwide. Subsequently, additional Direct-Acting Antivirals have been approved and therapeutic outcomes have shown further enhancement with negligible adverse reactions and approximately 100 percent clearance rates. Contemporary treatment protocols exclude interferon and predominantly exclude RBV while consisting of multiple DAA compounds. The review authors synthesized information on existing therapeutic approaches and explored potential challenges impeding hepatitis C eradication globally (Kim et al.,2005).

Hepatitis D

The management of chronic hepatitis D remains inadequate currently despite recent advancements in chronic viral hepatitis therapy. The existing therapeutic option consists of interferon-α (IFN) with efficacy linked to dosage amount and treatment duration. The occurrence of compelled elimination of hepatitis D virus (HDV) after completing a 12-month regimen with elevated doses of conventional IFN is nonetheless minimal. The IFN treatment should be continued as long as tolerated until hepatitis B surface antigen disappears, with medication amounts adjusted according to patient tolerance. However, due to their adverse reactions, which commonly occur, patients require ongoing clinical supervision. Although initial positive outcomes were observed with pegylated IFN, the rate of maintained virological improvement continues to be insufficient and recurrence frequency elevated, emphasizing the necessity to develop novel antivirals specifically designed to target this unique virus's life cycle (Farci et al.,2007).

Hepatitis E

The main cause of hepatitis is viral infection from the hepatitis E virus (HEV), although it may also develop into a long-term condition. No definitive treatment exists for acute hepatitis, with current protocols focusing on supportive care. For long-term HEV infection, ribavirin is the preferred medication, particularly for transplant recipients. Pegylated interferon has demonstrated efficacy in hepatitis E management despite significant adverse reactions. Bile flow obstruction represents one

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

of the most prevalent and potentially fatal manifestations of hepatitis E. Current HEV therapeutic approaches focus on addressing symptoms. Treatment typically involves multiple phases including nutritional supplementation with vitamins, administration of albumin and plasma, symptom management, ursodeoxycholic acid and S-adenosylmethionine, alongside Eastern herbal remedies to reduce jaundice. Individuals with pre-existing hepatic disorders risk progressing to hepatic insufficiency. These patients receive foundation care through supportive measures. Ribavirin therapy has shown effectiveness in preventing liver transplantation. Hepatic failure management includes prevention and treatment of complications. Hepatic support systems aim to maintain function until the organ regenerates or transplantation becomes possible. Liver replacement surgery remains considered the definitive curative intervention for acute-on-chronic hepatic failure, especially in cases unresponsive to supportive interventions intended to sustain vital functions (Hui et al.,2016).

Hepatitis control strategies

Viral hepatitis represents one of the most crucial worldwide health issues with an increasing global impact. Contamination with hepatitis B virus and hepatitis C virus significantly adds to enduring liver ailments. These infections can advance to liver fibrosis, hepatic carcinoma, and considerable fatality in impacted communities. Vaccination blocks the spread of hepatitis B virus. The medical treatments used persistently to manage the hepatitis B virus can suppress the advancement of liver conditions stemming from hepatitis B virus infection. Although a hepatitis C virus immunization is currently not available, hepatitis C virus infection may be managed through oral direct-acting antiviral medications. The World Health Organization (WHO) has pledged to help countries establish national targets to reduce new infections by 90 percent and obtain 80 percent comprehensive access to critical treatment services in an effort to eradicate viral hepatitis. This could lead to 65 percent reduction in viral hepatitis mortality figures. This section analyzes key attributes of viral hepatitis, treatment protocols endorsed by the WHO, and the present circumstance regarding management approaches for viral hepatitis in South Korea. To fulfill the aim of eliminating viral hepatitis by 2030 in South Korea, a specialized virtual unit focusing on viral hepatitis should be established within Centers for Disease Control & Prevention (CDC) to develop and execute a comprehensive plan for addressing viral hepatitis nationally (Sinn et al.,2017).

Conclusion

To conclude, Viral hepatitis continues to be among the crucially important health issues in the world, as millions of individuals are infected, and this disease results in tragic complications, such as cirrhosis, liver failure, hepatocellular Carcinoma (HCC). The rate of morbidity and mortality associated with forms of hepatitis is high A, B, C, D and E despite some medical achievements in the field of prevention, vaccination, and treatment, in particular in developing countries and regions as Pakistan because of the low awareness organizations and the poor health care system the rates of spreading are enormous. The highest percentage of people infected with hepatitis as a result of dirty sanitation system, unsafe injection practices at the health care facilities and no mass education on health care issues is found in Balochistan province comprising of Kech (Turbat) Quetta, and Panjgur. Low screening, immunization and access to antiviral agents are only associated with Pakistan and other resource-poor regions unlike, developed countries which have managed to bring down the rates of hepatitis occurrence due to vaccination and treatment efforts among the population during the screening procedures. The treatment options also differ depending on the type of hepatitis infection whereby, supportive care is provided in case of hepatitis A and E and antiviral therapy is provided in case of chronic hepatitis B and C. Drug resistance, cost of care and inaccessibility of care however are hindrances to effective management of the disease. Measures that prevent the spread include immunization campaigns, intervention measures to generate awareness and sanitation. And complex, since it will take government policy, health care system strengthening and international cooperation to respond appropriately to the issue of viral hepatitis. The

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

world can manage to meet the target, which the World Health Organization has set to eradicate viral hepatitis as a public health problem, by enhancing diagnosis rate, expanding the reach of vaccination, and, finally, by making treatment affordable and available.

REFERENCES

Aggarwal, R., &Jameel, S. (2011). Hepatitis e. *Hepatology*, *54*(6), 2218-2226.

Ahmed, S., & Baloch, M. A. (2017). Analysing the Socio-economic Factors Causing Hepatitis B and C in Balochistan A Case Study of Quetta District. Pakistan Study Centre, 5(1), 235-250.

Ali, A., Hasni, M. S., Rahim, M. C., Marri, F., Lal, A., &Faiz, S. (2024). Incidence, Risk Factors, Clinical and Sub-Clinical Aspects of Hepatitis A and B Patients among Ethnic Groups in Civil Hospital Turbat, District Kech, Balochistan. *Pak-Euro Journal of Medical and Life Sciences*, *7*(3), 571-580.

Burstow, N. J., Mohamed, Z., Gomaa, A. I., Sonderup, M. W., Cook, N. A., Waked, I.,. & Taylor-Robinson, S. D. (2017). Hepatitis C treatment: *International journal of general medicine*, 39-52.

Butt, A. S. (2015). Epidemiology of viral hepatitis and liver diseases in Pakistan. *Euroasian journal of hepato-gastroenterology*, *5*(1), 43.

Castaneda, D., Gonzalez, A. J., Alomari, M., Tandon, K., &Zervos, X. B. (2021). From hepatitis A to E: A critical review of viral hepatitis. *World journal of gastroenterology*, *27*(16), 1691.

Cheung, A., &Kwo, P. (2020). Viral hepatitis other than A, B, and C: evaluation and management. Clinics in liver disease, 24(3), 405-419.

Cuthbert, J. A. (2001). Hepatitis A: old and new. Clinical microbiology reviews, 14(1), 38-58.

Farci, P., Chessa, L., Balestrieri, C., Serra, G., & Lai, M. E. (2007). Treatment of chronic hepatitis D. Journal of viral hepatitis, 14, 58-63.

Guvenir, M., &Arikan, A. (2020). Hepatitis B virus: from diagnosis to treatment. Polish Journal of Microbiology, 69(4), 391.

Hui, W., Wei, L., Li, Z., & Guo, X. (2016). Treatment of hepatitis E. Hepatitis E Virus, 211-221.

Jonas, M. M. (2009). Hepatitis B and pregnancy: an underestimated issue. Liver international, 29, 133-139.

Khan, N. U., Zalan, A., Petruzziello, A., Haq, F., & Hayat, Y. (2018). Determining the actual prevalence of hepatitis B in Khyber Pakhtunkhwa-Pakistan: a meta-analysis. The open virology journal, 12, 33.

Kim, A. I., & Saab, S. (2005). Treatment of hepatitis C. The American journal of medicine, 118(8), 808-815.

Kruszon-Moran, D., Paulose-Ram, R., Martin, C. B., Barker, L. K., &McQuillan, G. (2020). Prevalence and trends in hepatitis B virus infection in the United States, 2015–2018.

Matheny, S. C., &Kingery, J. E. (2012). Hepatitis a. American family physician, 86(11), 1027-1034.

Nazeer, S., Iqbal, A., Baloch, M. C., Khan, B., Ismail, M., Iqbal, B., & Naseem, M. (2023). Prevalence, Risk Factors, and Associated Sub-Clinical Aspects of Hepatitis A, B And C in Ethnic Groups of Panjgur District, Balochistan. Pak-Euro Journal of Medical and Life Sciences, 6(2), 55-62.

Odenwald, M. A., & Paul, S. (2022). Viral hepatitis: Past, present, and future. *World journal of gastroenterology*, *28*(14), 1405.

Oliveira, C. P. M. S., Kappel, C. R., Siqueira, E. R., Lima, V. M. R., Stefano, J. T., Michalczuk, M. T., ... &Alvares-da-Silva, M. R. (2013). Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. International journal of cardiology, 164(2), 221-226.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Pisano, M. B., Giadans, C. G., Flichman, D. M., Ré, V. E., Preciado, M. V., &Valva, P. (2021). Viral hepatitis update: Progress and perspectives. *World journal of gastroenterology*, *27*(26), 4018.

Razzokberganova, D. O., Ibragimov, S. J., Yoqubov, Q. Y., &Atadjanova, O. N. (2025). NUTRITION IN VIRAL HEPATITIS. *Multidisciplinary Journal of Science and Technology*, *5*(3), 59-62.

Sadia, H., Bugti, N., Ashiq, S., Kalsoom, S., Baloch, H., Nawaz, A., & Akbar, A. (2022). Demographic Distribution of Viral Hepatitis in the Patients of District Quetta, Pakistan. RADS Journal of Biological Research & Applied Sciences, 13(1), 23-32.

Schillie, S. (2020). CDC recommendations for hepatitis C screening among adults—United States, 2020. *MMWR. Recommendations and Reports*, *69*.

Sinn, D. H., Cho, E. J., Kim, J. H., Kim, D. Y., Kim, Y. J., & Choi, M. S. (2017). Current status and strategies for viral hepatitis control in Korea. Clinical and molecular hepatology, 23(3), 189.

Suk-Fong Lok, A. (2019). Hepatitis B treatment: what we know now and what remains to be researched. Hepatology communications, 3(1), 8-19.

Webb, G. W., Kelly, S., & Dalton, H. R. (2020). Hepatitis A and hepatitis E: clinical and epidemiological features, diagnosis, treatment, and prevention. Clinical microbiology newsletter, 42(21), 171-179.